Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis
- PMID: 30887967
- DOI: 10.4193/Rhin18.274
Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis
Abstract
Background: Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms. However, the effects of azelastine to influence decongestion on human nasal mucosa in patients with allergic rhinitis are not yet fully explored and merit further exploration. The effects of azelastine on the vasocontractile responses generated by smooth muscles in the vascular structures of human nasal mucosa were investigated directly in vitro.
Methods: We examined the effectiveness of azelastine on isolated human nasal mucosa by testing: 1) the effect on mucosa resting tension; 2) the effect on mucosal contraction caused by 10-6 M methoxamine as a sympathetic mimetic; 3) the effect of the drugs on electrically induced mucosal contractions.
Results: The results indicated that addition of methoxamine to the incubation medium caused the nasal mucosa to contract in a dose-dependent manner. Addition of azelastine at doses of 10â€"6 M or above elicited a significant dilation response to 10â€"6 M methoxamine-induced mucosal contraction. Azelastine could inhibit electrical field stimulation-induced spike mucosal contraction. Moreover, increase in concentration of azelastine had minimal effect on basal tension of nasal mucosa.
Conclusions: The technique in our study is simple and reproducible. Azelastine could inhibit both EFS and methoxamine-induced nasal mucosal contractions in vitro. This study highlights that although azelastine nasal spray is often used in treating allergic rhinitis to improve symptoms, nasal obstruction may be not relieved immediately due to the anti-sympathetic effect of azelastine.
Similar articles
-
Effects of montelukast on human nasal mucosa.Eur Arch Otorhinolaryngol. 2019 Mar;276(3):761-765. doi: 10.1007/s00405-018-05274-8. Epub 2019 Jan 2. Eur Arch Otorhinolaryngol. 2019. PMID: 30604060
-
Azelastine nasal spray inhibiting parasympathetic function of tracheal smooth muscle.Rhinology. 2010 Jun;48(2):211-5. doi: 10.4193/Rhin09.109. Rhinology. 2010. PMID: 20502763
-
Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis.Allergy Asthma Proc. 2003 Mar-Apr;24(2):95-105. Allergy Asthma Proc. 2003. PMID: 12776442 Review.
-
Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis.Ann Allergy Asthma Immunol. 2003 Sep;91(3):258-62. doi: 10.1016/S1081-1206(10)63527-2. Ann Allergy Asthma Immunol. 2003. PMID: 14533657 Clinical Trial.
-
Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.Curr Med Res Opin. 2007 Oct;23(10):2441-52. doi: 10.1185/030079907X226302. Curr Med Res Opin. 2007. PMID: 17723160 Review.
Cited by
-
Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission.Theranostics. 2021 Jan 1;11(4):1828-1844. doi: 10.7150/thno.48698. eCollection 2021. Theranostics. 2021. PMID: 33408784 Free PMC article.
-
Novel Pyran-Linked Phthalazinone-Pyrazole Hybrids: Synthesis, Cytotoxicity Evaluation, Molecular Modeling, and Descriptor Studies.Front Chem. 2021 May 24;9:666573. doi: 10.3389/fchem.2021.666573. eCollection 2021. Front Chem. 2021. PMID: 34109154 Free PMC article.
-
Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals.Indian J Ophthalmol. 2020 Jul;68(7):1349-1356. doi: 10.4103/ijo.IJO_1589_20. Indian J Ophthalmol. 2020. PMID: 32587162 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources